FAQ   Szukaj   Użytkownicy   Grupy   Rejestracja   Profil   Zaloguj się, by sprawdzić wiadomości   Zaloguj 
GLP-1 and Genes Linked to CV Risk with Intensive DM Therapy

 
Napisz nowy temat   Odpowiedz do tematu    Forum Forum Nieruchomości Strona Główna -> Nieruchomości - dyskusje ogólne
Zobacz poprzedni temat :: Zobacz następny temat  
Autor Wiadomość
upamfva
Ekspert
Ekspert


Dołączył: 05 Maj 2021
Posty: 2509

PostWysłany: Wto Cze 14, 2022 11:38 pm    Temat postu: GLP-1 and Genes Linked to CV Risk with Intensive DM Therapy Odpowiedz z cytatem

GLP-1 and Genes Linked to CV Risk with Intensive DM Therapy



Is GLP-1 part of the answer to why cardiac mortality tends to be higher in diabetes patients treated with intensive glycemic control? To get more news about GLP GRS, you can visit glprobotics.com official website.

A new study has shown light on why some people treated with intensive glycemic control may be at increased risk for cardiac events, while others seem to benefit.

Results were published online on November 28, 2017 in Diabetes Care, and “highlight the importance of GLP-1 as a cardioprotective factor,” according to first author Hetal Shah, MBBS, of Harvard Medical School, and colleagues.1
Intensive glycemic control has been proposed as one strategy to decrease the risk of CVD in T2D, but the approach is controversial. Results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study showed that patients with T2D who were at high CV risk and received intensive glycemic control had significantly lower rates of myocardial infarction than those treated with standard therapy. However, the trial was stopped early due to a seemingly paradoxical increase in CV mortality with intensive therapy.2

Researchers later conducted a genome-wide association study (GWAS) in a subset of ACCORD participants. That study identified two genetic variants (rs57922 and rs9299870) significantly associated with increased CV mortality in patients treated with intensive glycemic control.3

Further work resulted in the development of a genetic risk score (GRS) derived from these two genetic variants. In patients with a GRS of 0, intensive therapy was protective from cardiac events. In patients with a GRS ≥2, intensive therapy was associated with increased cardiac mortality.3

To begin to understand underlying mechanisms, researchers evaluated a subset of 351 participants who were part of the ACCORD study or a related study called ACCORD-MIND. Included participants had both GWAS data and data on 65 biomarkers related to metabolism, CVD, endocrine and immune function, and sepsis/apoptosis at baseline and 12 months after randomization to intensive glycemic control or standard therapy.

Statistical modeling was used to investigate the link between GRS at baseline and 12-month change in biomarker levels.

Results in the intensive therapy arm showed that each unit increase in GRS was linked to 22% decrease in change in active GLP-1 levels from baseline to 12 months (P = 3 x 10-4), with the effect driven by rs57922 (P = 5 x 10-4). The standard therapy arm showed no such association.
Furthermore, C/C homozygotes previously found to derive CV benefits from intensive treatment had a 22% increase in active GLP-1 levels between baseline and 12 months. Active GLP-1 levels were unmodified in C/T heterozygotes. And, T/T homozygotes found to have increased CV mortality with intensive treatment, had a 28% decrease in GLP-1 levels.
Adjusting for baseline CVD, diabetes duration, HbA1c, fasting plasma glucose, heart rate, smoking, age, and sex did change the results.
Carriers of rs9299870 showed a tendency toward higher active GLP-1 at baseline, but there was no significant change at 12 months.
While the mechanisms of how rs57922 may affect active GLP-1 levels remains unclear, one possibility is that it may be associated with lower expression of genes involved in GLP-1 synthesis, secretion and/or processing during intensive glycemic control. Having a genetic variant that decreases GLP-1 levels may decrease the cardioprotective effects GLP-1 appears to have on glucose metabolism, as well as on acute and chronic stress. It may also affect GLP-1’s anti-inflammatory effects on cells involved in atherogenesis.

However, the authors pointed out that the changes in GLP-1 seen in this study were much smaller than those associated with therapeutic doses. Whether or not such small changes can influence CV risk is open to question.
Other limitations include a relatively small sample size, precluding the evaluation of CV outcomes. Also, the study included only Caucasian participants with an average age of 62-63 years, and the results may not apply to other populations.

Nevertheless, the authors concluded: “[O]ur results suggest a possible role of diminished GLP-1 activity as a factor for increased cardiac mortality during intensive glycemic therapy in rs57922 T/T homozygotes, possibly via impaired cardio- and/or stress-protective mechanisms or enhanced inflammatory pathways. Further studies seeking replication of this observation in other data sets and exploring the underlying mechanisms are warranted.”
Powrót do góry
Ogląda profil użytkownika Wyślij prywatną wiadomość
Mieszkaniowy






Wysłany:     Temat postu: Ogłoszenia z portalu

Ładowanie ogłoszeń...
Powrót do góry
Wyświetl posty z ostatnich:   
Napisz nowy temat   Odpowiedz do tematu    Forum Forum Nieruchomości Strona Główna -> Nieruchomości - dyskusje ogólne Wszystkie czasy w strefie CET (Europa)
Strona 1 z 1

 
Skocz do:  
Nie możesz pisać nowych tematów
Nie możesz odpowiadać w tematach
Nie możesz zmieniać swoich postów
Nie możesz usuwać swoich postów
Nie możesz głosować w ankietach


Powered by phpBB © 2001, 2005 phpBB Group

Nieruchomości | Kredyt Mieszkaniowy